Abeona Therapeutics Stock Forum

$Abeona Therapeutics (ABEO.US)$
Abeona Strengthens to $98M Cash Position as FDA Decision for Pz-cel Approaches

$Abeona Therapeutics (ABEO.US)$ FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025

$Abeona Therapeutics (ABEO.US)$ Reuters
just
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-Cel

$Abeona Therapeutics (ABEO.US)$ Abeona Therapeutics Concludes Type A Meeting With FDA To Align On Upcoming Pz-cel BLA Resubmission, Continues To Expect To Resubmit BLA In Second Half Of 2024

$Abeona Therapeutics (ABEO.US)$
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type a Meeting With FDA to Align on Upcoming Pz-Cel Bla Resubmission
Abeona Therapeutics Q2 Income From Operations USD -17.864 Million Vs. IBES Estimate USD -14.6 Million
Abeona Therapeutics 2Q Loss/Shr 26c
Abeona Therapeutics 2Q Net $7.41M
Abeona Therapeutics Q2 Cash & Investments USD 123 Million

$Abeona Therapeutics (ABEO.US)$ Abeona Therapeutics: Beacon to Have Right to Evaluate, for 12-Month Period, Aav204 Capsid for Potential Use in Certain Ophthalmology Indications
Abeona Therapeutics: To Get Upfront Payment Upon Beacon's Exercise of Option to License Aav204, With Extra Payments on Achievement of Milestones

$Abeona Therapeutics (ABEO.US)$ Wow.. price target adjusted lower from $28 to $21 and the stock drops like that… still a big upside imo.

$Abeona Therapeutics (ABEO.US)$
NEWS
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Abeona Therapeutics Inc. announced the pricing of an underwritten offering of common stock and pre-funded warrants, expected to generate approximately $75 million in gross proceeds. The offering includes both new and existing investors, with the funds intended for the resubmission of its BLA, commercialization of its product candidate pz-cel, and ...

📣 3 PDUFAs left in April! See summary 👇
🗓️ Last week’s PDUFAs:
$Pfizer (PFE.US)$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals (DAWN.US)$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio (IBRX.US)$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics (ABEO.US)$ : CRL 4/22 🙁
⚠...